Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4635 combinations in prostate cancer
NCT04089553Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imaradenant in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started Aug 2019; status: completed.
02
Drugs
imaradenant
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04089553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089553.